Molecular subtyping in urothelial carcinoma treatment

被引：1
作者：
Wu, Xiaowen [1 ]
Sheng, Xinan [1 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Genitourinary Oncol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
来源：
CANCER CELL | 2024年 / 42卷 / 12期
关键词：
D O I：
10.1016/j.ccell.2024.11.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The heterogeneity of urothelial carcinoma (UC) and variable treatment responses poses significant clinical challenges. In this issue of Cancer Cell, Hamidi et al. conducted a multi-omics analysis of 2,803 UC patients from four clinical trials with anti-PD-L1, revealing four transcriptional subtypes. This approach could help tailor therapies for UC.
引用
收藏
页码：1993 / 1996
页数：4
相关论文
共 10 条
  • [1] Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
    Bajorin, DF
    Dodd, PM
    Mazumdar, M
    Fazzari, M
    McCaffrey, JA
    Scher, HI
    Herr, H
    Higgins, G
    Boyle, MG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) : 3173 - 3181
  • [2] Galsky M.D., 2024, Ann. Oncol., V35, pS1138, DOI [10.1016/j.annonc.2024.08.2052, DOI 10.1016/J.ANNONC.2024.08.2052]
  • [3] Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
    Hamidi, Habib
    Senbabaoglu, Yasin
    Beig, Niha
    Roels, Juliette
    Manuel, Cyrus
    Guan, Xiangnan
    Koeppen, Hartmut
    Assaf, Zoe June
    Nabet, Barzin Y.
    Waddell, Adrian
    Yuen, Kobe
    Maund, Sophia
    Sokol, Ethan
    Giltnane, Jennifer M.
    Schedlbauer, Amber
    Fuentes, Eloisa
    Cowan, James D.
    Kadel, Edward E.
    Degaonkar, Viraj
    Andreev-Drakhlin, Alexander
    Williams, Patrick
    Carter, Corey
    Gupta, Suyasha
    Steinberg, Elizabeth
    Loriot, Yohann
    Bellmunt, Joaquim
    Grivas, Petros
    Rosenberg, Jonathan
    van der Heijden, Michiel S.
    Galsky, Matthew D.
    Powles, Thomas
    Mariathasan, Sanjeev
    Banchereau, Romain
    [J]. CANCER CELL, 2024, 42 (12) : 2098 - 2112.e4
  • [4] Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection
    Meeks, Joshua J.
    Black, Peter C.
    Galsky, Matthew
    Grivas, Petros
    Hahn, Noah M.
    Hussain, Syed A.
    Milowsky, Matthew I.
    Steinberg, Gary D.
    Svatek, Robert S.
    Rosenberg, Jonathan E.
    [J]. EUROPEAN UROLOGY, 2023, 84 (05) : 473 - 483
  • [5] Progress in systemic therapy for advanced-stage urothelial carcinoma
    Nadal, Rosa
    Valderrama, Begona P.
    Bellmunt, Joaquim
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (01) : 8 - 27
  • [6] Robertson AG, 2017, CELL, V171, P540, DOI [10.1016/j.cell.2018.07.036, 10.1016/j.cell.2017.09.007]
  • [7] Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials
    Sheng, Xinan
    Wang, Lin
    He, Zhisong
    Shi, Yanxia
    Luo, Hong
    Han, Weiqing
    Yao, Xin
    Shi, Benkang
    Liu, Jiyan
    Hu, Changlu
    Liu, Ziling
    Guo, Hongqian
    Yu, Guohua
    Ji, Zhigang
    Ying, Jianming
    Ling, Yun
    Yu, Shiying
    Hu, Yi
    Guo, Jianming
    Fang, Jianmin
    Zhou, Aiping
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12) : 1391 - 1402
  • [8] Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification
    Sjodahl, Gottfrid
    Eriksson, Pontus
    Liedberg, Fredrik
    Hoglund, Mattias
    [J]. JOURNAL OF PATHOLOGY, 2017, 242 (01) : 113 - 125
  • [9] Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials
    Sonpavde, Guru
    Pond, Gregory R.
    Fougeray, Ronan
    Choueiri, Toni K.
    Qu, Angela Q.
    Vaughn, David J.
    Niegisch, Guenter
    Albers, Peter
    James, Nicholas D.
    Wong, Yu-Ning
    Ko, Yoo-Joung
    Sridhar, Srikala S.
    Galsky, Matthew D.
    Petrylak, Daniel P.
    Vaishampayan, Ulka N.
    Khan, Awais
    Vogelzang, Nicholas J.
    Beer, Tomasz M.
    Stadler, Walter M.
    O'Donnell, Peter H.
    Sternberg, Cora N.
    Rosenberg, Jonathan E.
    Bellmunt, Joaquim
    [J]. EUROPEAN UROLOGY, 2013, 63 (04) : 717 - 723
  • [10] Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
    Yan, X. Q.
    Yey, M. J.
    Zou, Q.
    Chen, P.
    He, Z. S.
    Wu, B.
    He, D. L.
    He, C. H.
    Xue, X. Y.
    Ji, Z. G.
    Chen, H.
    Zhang, S.
    Liu, Y. P.
    Zhang, X. D.
    Fu, C.
    Xu, D. F.
    Qiu, M. X.
    Lv, J. J.
    Huang, J.
    Ren, X. B.
    Cheng, Y.
    Qin, W. J.
    Zhang, X.
    Zhou, F. J.
    Ma, L. L.
    Guo, J. M.
    Ding, D. G.
    Wei, S. Z.
    He, Y.
    Guo, H. Q.
    Shi, B. K.
    Liu, L.
    Liu, F.
    Hu, Z. Q.
    Jin, X. M.
    Yang, L.
    Zhu, S. X.
    Liu, J. H.
    Huang, Y. H.
    Xu, T.
    Liu, B.
    Sun, T.
    Wang, Z. J.
    Jiang, H. W.
    Yu, D. X.
    Zhou, A. P.
    Jiang, J.
    Luan, G. D.
    Jin, C. L.
    Xu, J.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (02) : 190 - 199
1